In the first quarter of 2012, publicly traded companies in the cell-based therapy industry continued to show promising overall growth. Highlights included $85 million in new capital investment and steady clinical trial progress.
Click here to download the full report
Erik Miljan believes that the actual value is several fold higher, find out more at our 3 day Stem Cells course. Understand different types of stem cells, the mode of action of stem cells and impact of recent advances on the commercial market.